AR-V7在前列腺癌进展及骨转移中的表达及临床意义

发布时间：2018-06-19 23:32

本文选题：前列腺癌 + 雄激素受体剪切变异体　；参考：《南昌大学》2017年硕士论文

【摘要】：目的:前列腺癌去势抵抗和远处转移是治疗的难点,其发生的确切机制目前尚不明确。大量研究表明雄激素受体剪切变异体与前列腺癌的进展和转移有密切关系。本研究拟探索AR-V7表达在前列腺癌进展及其骨转移过程中的临床意义。方法:筛选2015年1月-2017年4月在南昌大学第一附属医院泌尿外科就诊且相关检查资料完整的51例患者作为研究对象。51例患者中前列腺增生患者20例,年龄58-77(平均65.8)岁;局限性前列腺癌患者20例,年龄59-76(平均67.5)岁;前列腺癌伴骨转移患者11例,年龄52-81(平均66)岁。三组患者的年龄差异无统计学意义。所有患者均经过手术后的病理检查确诊,收集患者手术后的前列腺病理组织标本。采用免疫组化染色法和qRT-PCR分别检测AR-V7蛋白和AR-V7m RNA在前列腺增生组织、局限性前列腺癌组织、伴骨转移的前列腺癌组织中表达情况。利用SPSS20.0统计软件分析三组标本中AR-V7的表达量差异。结果:1、AR-V7蛋白的表达以细胞核中出现棕黄色颗粒为阳性表达。免疫组化显示AR-V7在三组不同前列腺标本中的阳性表达量分别为:前列腺增生标本组中无阳性表达;局限性前列腺癌标本组有3例阳性表达,该组阳性表达率15%;前列腺癌伴骨转移标本组AR-V7有6例阳性表达,该组阳性表达率54.5%,差异有统计学意义(P0.005)。2、qRT-PCR检测组织标本结果显示:前列腺病理标本中AR-V7 m RNA表达量在前列腺增生组、局限性前列腺癌组、前列腺癌伴骨转移组依次显著上调,差异有统计学意义(P0.05)。结论:AR-V7的表达量在前列腺增生、局限性前列腺癌、伴骨转移的前列腺癌病理组织中依次增高。AR-V7可能与前列腺癌进展和骨转移的发生密切相关。
[Abstract]:Objective: castration resistance and distant metastasis of prostate cancer are difficult to be treated. A large number of studies have shown that androgen receptor splicing variants are closely related to the progression and metastasis of prostate cancer. This study was to explore the clinical significance of AR-V 7 expression in the progression and bone metastasis of prostate cancer. Methods: from January 2015 to April 2017, 51 patients with benign prostatic hyperplasia (BPH), aged 58-77 (mean 65.8 years), were selected from urology department of the first affiliated Hospital of Nanchang University. There were 20 patients with localized prostate cancer (mean 67.5 years old) and 11 patients with prostate cancer with bone metastasis (mean 66 years old). There was no significant difference in age among the three groups. All the patients were confirmed by pathological examination after operation, and the pathological specimens of prostate were collected. Immunohistochemical staining and qRT-PCR were used to detect the expression of AR-V7 protein and AR-V7 mRNA in prostatic hyperplasia tissues, localized prostate cancer tissues and prostate cancer tissues with bone metastasis, respectively. The expression of AR-V7 in the three groups was analyzed by SPSS 20.0 software. Results the positive expression of AR-V 7 protein in the nucleus was found in brown granules. Immunohistochemical staining showed that there was no positive expression of AR-V7 in three groups of prostate specimens: no positive expression of AR-V7 was found in benign prostatic hyperplasia group and 3 cases in localized prostate cancer group. There were 6 cases of AR-V7 positive expression in prostate cancer with bone metastasis. The positive expression rate of AR-V7 mRNA was significantly higher in prostate hyperplasia group, localized prostate cancer group and prostate cancer with bone metastasis group. The difference was statistically significant (P 0.05). Conclusion the increased expression of V7 in prostate cancer tissues with benign prostatic hyperplasia, localized prostate cancer and bone metastasis may be closely related to the progression of prostate cancer and the occurrence of bone metastasis.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.25

【参考文献】